Several local pharmas hit over a trillion won during the year.
South Korea’s major drug and biopharmaceutical companies saw their sales surge in 2020, with 11 local pharma firms registering sales of over $910m (KRW1t) during the year, Yonhap reported.
For instance, contract manufacturing organization giant Samsung Biologics, the biopharmaceutical arm of top conglomerate Samsung Group, posted sales of more than $910m (KRW1t) for the first time since its inception in 2011.
Celltrion and affiliate Celltrion Healthcare remained in the trillion-won club last year, with their sales for the first three quarters alone surpassing the milestone.
Meanwhile, Chong Kun Dang saw its sales jump 21%, with the top line of Green Cross climbing nearly 11%.
Do you know more about this story? Contact us anonymously through this link.